Is SGMT or OLMA more profitable?

Sagimet Biosciences' return on equity of -37.57% beat Olema Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Sagimet Biosciences N/A -37.57% -35.52% Olema Pharmaceuticals N/A -46.00% -41.22%

Does the media favor KURA or SGMT?

In the previous week, Kura Oncology had 2 more articles in the media than Sagimet Biosciences. MarketBeat recorded 3 mentions for Kura Oncology and 1 mentions for Sagimet Biosciences. Sagimet Biosciences' average media sentiment score of 0.00 beat Kura Oncology's score of -0.45 indicating that Sagimet Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kura Oncology 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Sagimet Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer ESPR or SGMT?

In the previous week, Esperion Therapeutics had 5 more articles in the media than Sagimet Biosciences. MarketBeat recorded 6 mentions for Esperion Therapeutics and 1 mentions for Sagimet Biosciences. Esperion Therapeutics' average media sentiment score of 0.12 beat Sagimet Biosciences' score of 0.00 indicating that Esperion Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Esperion Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Sagimet Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is LBRX or SGMT more profitable?

LB Pharmaceuticals' return on equity of 0.00% beat Sagimet Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets LB Pharmaceuticals N/A N/A N/A Sagimet Biosciences N/A -37.57% -35.52%

Does the media refer more to LBRX or SGMT?

In the previous week, LB Pharmaceuticals had 1 more articles in the media than Sagimet Biosciences. MarketBeat recorded 2 mentions for LB Pharmaceuticals and 1 mentions for Sagimet Biosciences. LB Pharmaceuticals' average media sentiment score of 0.36 beat Sagimet Biosciences' score of 0.00 indicating that LB Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment LB Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Sagimet Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is SGMT or SANA more profitable?

Sagimet Biosciences' return on equity of -37.57% beat Sana Biotechnology's return on equity. Company Net Margins Return on Equity Return on Assets Sagimet Biosciences N/A -37.57% -35.52% Sana Biotechnology N/A -108.01% -40.68%

Sagimet Biosciences (SGMT) Competitors

$6.93 -0.13 (-1.84%)

Closing price 04:00 PM Eastern

Extended Trading

$6.95 +0.02 (+0.26%)

As of 07:55 PM Eastern

Compare

SGMT vs. OLMA, KURA, ESPR, LBRX, and SANA

Should you buy Sagimet Biosciences stock or one of its competitors? MarketBeat compares Sagimet Biosciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Sagimet Biosciences include Olema Pharmaceuticals (OLMA), Kura Oncology (KURA), Esperion Therapeutics (ESPR), LB Pharmaceuticals (LBRX), and Sana Biotechnology (SANA). These companies are all part of the "pharmaceutical products" industry.

How does Sagimet Biosciences compare to Olema Pharmaceuticals?

Sagimet Biosciences (NASDAQ:SGMT) and Olema Pharmaceuticals (NASDAQ:OLMA) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, earnings, media sentiment, institutional ownership, profitability and dividends.

Sagimet Biosciences has higher revenue and earnings than Olema Pharmaceuticals. Olema Pharmaceuticals is trading at a lower price-to-earnings ratio than Sagimet Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sagimet Biosciences	$2M	112.89	-$51.04M	-$1.34	N/A
Olema Pharmaceuticals	N/A	N/A	-$162.45M	-$2.02	N/A

In the previous week, Sagimet Biosciences had 1 more articles in the media than Olema Pharmaceuticals. MarketBeat recorded 1 mentions for Sagimet Biosciences and 0 mentions for Olema Pharmaceuticals. Sagimet Biosciences' average media sentiment score of 0.00 beat Olema Pharmaceuticals' score of -1.57 indicating that Sagimet Biosciences is being referred to more favorably in the media.

Company	Overall Sentiment
Sagimet Biosciences	Neutral
Olema Pharmaceuticals	Very Negative

Sagimet Biosciences presently has a consensus price target of $25.57, suggesting a potential upside of 269.00%. Olema Pharmaceuticals has a consensus price target of $44.10, suggesting a potential upside of 295.87%. Given Olema Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Olema Pharmaceuticals is more favorable than Sagimet Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sagimet Biosciences	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64
Olema Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.71

Sagimet Biosciences has a beta of 3.41, meaning that its stock price is 241% more volatile than the broader market. Comparatively, Olema Pharmaceuticals has a beta of 1.98, meaning that its stock price is 98% more volatile than the broader market.

87.9% of Sagimet Biosciences shares are held by institutional investors. Comparatively, 91.8% of Olema Pharmaceuticals shares are held by institutional investors. 14.7% of Sagimet Biosciences shares are held by company insiders. Comparatively, 12.6% of Olema Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Sagimet Biosciences' return on equity of -37.57% beat Olema Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sagimet Biosciences	N/A	-37.57%	-35.52%
Olema Pharmaceuticals	N/A	-46.00%	-41.22%

Summary

Sagimet Biosciences beats Olema Pharmaceuticals on 10 of the 14 factors compared between the two stocks.

How does Sagimet Biosciences compare to Kura Oncology?

Kura Oncology (NASDAQ:KURA) and Sagimet Biosciences (NASDAQ:SGMT) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, earnings, analyst recommendations, media sentiment, dividends and profitability.

In the previous week, Kura Oncology had 2 more articles in the media than Sagimet Biosciences. MarketBeat recorded 3 mentions for Kura Oncology and 1 mentions for Sagimet Biosciences. Sagimet Biosciences' average media sentiment score of 0.00 beat Kura Oncology's score of -0.45 indicating that Sagimet Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kura Oncology	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Sagimet Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Kura Oncology has a beta of 0.36, meaning that its stock price is 64% less volatile than the broader market. Comparatively, Sagimet Biosciences has a beta of 3.41, meaning that its stock price is 241% more volatile than the broader market.

Sagimet Biosciences has lower revenue, but higher earnings than Kura Oncology. Sagimet Biosciences is trading at a lower price-to-earnings ratio than Kura Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kura Oncology	$67.48M	13.97	-$278.67M	-$3.35	N/A
Sagimet Biosciences	$2M	112.89	-$51.04M	-$1.34	N/A

87.9% of Sagimet Biosciences shares are held by institutional investors. 7.6% of Kura Oncology shares are held by insiders. Comparatively, 14.7% of Sagimet Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Sagimet Biosciences has a net margin of 0.00% compared to Kura Oncology's net margin of -411.19%. Sagimet Biosciences' return on equity of -37.57% beat Kura Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kura Oncology	-411.19%	-141.95%	-43.28%
Sagimet Biosciences	N/A	-37.57%	-35.52%

Kura Oncology presently has a consensus target price of $25.46, suggesting a potential upside of 139.75%. Sagimet Biosciences has a consensus target price of $25.57, suggesting a potential upside of 269.00%. Given Sagimet Biosciences' higher probable upside, analysts plainly believe Sagimet Biosciences is more favorable than Kura Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kura Oncology	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69
Sagimet Biosciences	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64

Summary

Sagimet Biosciences beats Kura Oncology on 11 of the 16 factors compared between the two stocks.

How does Sagimet Biosciences compare to Esperion Therapeutics?

Esperion Therapeutics (NASDAQ:ESPR) and Sagimet Biosciences (NASDAQ:SGMT) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, earnings, analyst recommendations, valuation, institutional ownership, dividends, risk and media sentiment.

47.4% of Esperion Therapeutics shares are owned by institutional investors. Comparatively, 87.9% of Sagimet Biosciences shares are owned by institutional investors. 1.6% of Esperion Therapeutics shares are owned by company insiders. Comparatively, 14.7% of Sagimet Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Esperion Therapeutics presently has a consensus price target of $5.54, indicating a potential upside of 75.87%. Sagimet Biosciences has a consensus price target of $25.57, indicating a potential upside of 269.00%. Given Sagimet Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe Sagimet Biosciences is more favorable than Esperion Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Esperion Therapeutics	1 Sell rating(s)	6 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Sagimet Biosciences	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64

Esperion Therapeutics has a beta of 1.07, indicating that its stock price is 7% more volatile than the broader market. Comparatively, Sagimet Biosciences has a beta of 3.41, indicating that its stock price is 241% more volatile than the broader market.

Esperion Therapeutics has a net margin of 0.12% compared to Sagimet Biosciences' net margin of 0.00%. Esperion Therapeutics' return on equity of -0.14% beat Sagimet Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Esperion Therapeutics	0.12%	-0.14%	0.12%
Sagimet Biosciences	N/A	-37.57%	-35.52%

In the previous week, Esperion Therapeutics had 5 more articles in the media than Sagimet Biosciences. MarketBeat recorded 6 mentions for Esperion Therapeutics and 1 mentions for Sagimet Biosciences. Esperion Therapeutics' average media sentiment score of 0.12 beat Sagimet Biosciences' score of 0.00 indicating that Esperion Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Esperion Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Sagimet Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Esperion Therapeutics has higher revenue and earnings than Sagimet Biosciences. Esperion Therapeutics is trading at a lower price-to-earnings ratio than Sagimet Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Esperion Therapeutics	$403.14M	2.01	-$22.68M	-$0.06	N/A
Sagimet Biosciences	$2M	112.89	-$51.04M	-$1.34	N/A

Summary

Esperion Therapeutics and Sagimet Biosciences tied by winning 8 of the 16 factors compared between the two stocks.

How does Sagimet Biosciences compare to LB Pharmaceuticals?

LB Pharmaceuticals (NASDAQ:LBRX) and Sagimet Biosciences (NASDAQ:SGMT) are both small-cap pharmaceutical products companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, media sentiment, earnings, dividends and risk.

In the previous week, LB Pharmaceuticals had 1 more articles in the media than Sagimet Biosciences. MarketBeat recorded 2 mentions for LB Pharmaceuticals and 1 mentions for Sagimet Biosciences. LB Pharmaceuticals' average media sentiment score of 0.36 beat Sagimet Biosciences' score of 0.00 indicating that LB Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
LB Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Sagimet Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

LB Pharmaceuticals has higher earnings, but lower revenue than Sagimet Biosciences. LB Pharmaceuticals is trading at a lower price-to-earnings ratio than Sagimet Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LB Pharmaceuticals	N/A	N/A	-$25.20M	-$1.73	N/A
Sagimet Biosciences	$2M	112.89	-$51.04M	-$1.34	N/A

LB Pharmaceuticals currently has a consensus price target of $38.40, indicating a potential upside of 25.98%. Sagimet Biosciences has a consensus price target of $25.57, indicating a potential upside of 269.00%. Given Sagimet Biosciences' higher probable upside, analysts clearly believe Sagimet Biosciences is more favorable than LB Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LB Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75
Sagimet Biosciences	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64

87.9% of Sagimet Biosciences shares are owned by institutional investors. 5.8% of LB Pharmaceuticals shares are owned by company insiders. Comparatively, 14.7% of Sagimet Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

LB Pharmaceuticals' return on equity of 0.00% beat Sagimet Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LB Pharmaceuticals	N/A	N/A	N/A
Sagimet Biosciences	N/A	-37.57%	-35.52%

Summary

LB Pharmaceuticals and Sagimet Biosciences tied by winning 7 of the 14 factors compared between the two stocks.

How does Sagimet Biosciences compare to Sana Biotechnology?

Sagimet Biosciences (NASDAQ:SGMT) and Sana Biotechnology (NASDAQ:SANA) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, profitability, analyst recommendations, earnings, media sentiment and risk.

87.9% of Sagimet Biosciences shares are held by institutional investors. Comparatively, 88.2% of Sana Biotechnology shares are held by institutional investors. 14.7% of Sagimet Biosciences shares are held by insiders. Comparatively, 25.4% of Sana Biotechnology shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Sagimet Biosciences has a beta of 3.41, meaning that its share price is 241% more volatile than the broader market. Comparatively, Sana Biotechnology has a beta of 2.14, meaning that its share price is 114% more volatile than the broader market.

Sagimet Biosciences' return on equity of -37.57% beat Sana Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sagimet Biosciences	N/A	-37.57%	-35.52%
Sana Biotechnology	N/A	-108.01%	-40.68%

In the previous week, Sagimet Biosciences had 1 more articles in the media than Sana Biotechnology. MarketBeat recorded 1 mentions for Sagimet Biosciences and 0 mentions for Sana Biotechnology. Sagimet Biosciences' average media sentiment score of 0.00 equaled Sana Biotechnology'saverage media sentiment score.

Company	Overall Sentiment
Sagimet Biosciences	Neutral
Sana Biotechnology	Neutral

Sagimet Biosciences presently has a consensus target price of $25.57, suggesting a potential upside of 269.00%. Sana Biotechnology has a consensus target price of $9.50, suggesting a potential upside of 189.63%. Given Sagimet Biosciences' higher probable upside, equities research analysts clearly believe Sagimet Biosciences is more favorable than Sana Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sagimet Biosciences	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64
Sana Biotechnology	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67

Sagimet Biosciences has higher revenue and earnings than Sana Biotechnology. Sagimet Biosciences is trading at a lower price-to-earnings ratio than Sana Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sagimet Biosciences	$2M	112.89	-$51.04M	-$1.34	N/A
Sana Biotechnology	N/A	N/A	-$244.17M	-$0.93	N/A

Summary

Sagimet Biosciences beats Sana Biotechnology on 8 of the 13 factors compared between the two stocks.

Get Sagimet Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SGMT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SGMT vs. The Competition

Export

Metric	Sagimet Biosciences	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$230.05M	$3.49B	$6.74B	$12.32B
Dividend Yield	N/A	2.28%	2.68%	5.88%
P/E Ratio	-5.17	20.50	25.39	23.96
Price / Sales	112.89	328.65	530.17	107.90
Price / Cash	N/A	130.96	45.29	53.76
Price / Book	2.03	8.26	10.76	6.41
Net Income	-$51.04M	$23.91M	$3.56B	$337.14M
7 Day Performance	6.13%	3.05%	1.37%	-0.48%
1 Month Performance	-2.26%	2.40%	0.81%	0.49%
1 Year Performance	-29.50%	56.35%	30.53%	28.16%

Sagimet Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SGMT Sagimet Biosciences	2.4586 of 5 stars	$6.93 -1.8%	$25.57 +269.0%	-15.6%	$230.05M	$2M	N/A	8
OLMA Olema Pharmaceuticals	1.9074 of 5 stars	$9.49 -4.0%	$44.10 +364.9%	+151.3%	$827.47M	N/A	N/A	70	Negative News
KURA Kura Oncology	3.3345 of 5 stars	$9.30 -2.6%	$25.46 +173.9%	+76.8%	$825.12M	$67.48M	N/A	130	Insider Trade
ESPR Esperion Therapeutics	3.3458 of 5 stars	$3.16 +0.2%	$5.54 +75.6%	+203.8%	$813.01M	$403.14M	N/A	200	News Coverage
LBRX LB Pharmaceuticals	2.0835 of 5 stars	$27.96 -1.9%	$38.40 +37.4%	N/A	$803.16M	N/A	N/A	16	Analyst Upgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SGMT) was last updated on 6/24/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Sagimet Biosciences (SGMT) Competitors

SGMT vs. OLMA, KURA, ESPR, LBRX, and SANA

How does Sagimet Biosciences compare to Olema Pharmaceuticals?

Summary

How does Sagimet Biosciences compare to Kura Oncology?

Summary

How does Sagimet Biosciences compare to Esperion Therapeutics?

Summary

How does Sagimet Biosciences compare to LB Pharmaceuticals?

Summary

How does Sagimet Biosciences compare to Sana Biotechnology?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SGMT vs. The Competition

Sagimet Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Sagimet Biosciences (SGMT) Competitors

SGMT vs. OLMA, KURA, ESPR, LBRX, and SANA

How does Sagimet Biosciences compare to Olema Pharmaceuticals?

Which has higher earnings & valuation, SGMT or OLMA?

Does the media prefer SGMT or OLMA?

Do analysts recommend SGMT or OLMA?

Which has more risk and volatility, SGMT or OLMA?

Do insiders & institutionals believe in SGMT or OLMA?

Is SGMT or OLMA more profitable?

Summary

How does Sagimet Biosciences compare to Kura Oncology?

Does the media favor KURA or SGMT?

Which has more risk and volatility, KURA or SGMT?

Which has stronger earnings and valuation, KURA or SGMT?

Do insiders and institutionals hold more shares of KURA or SGMT?

Is KURA or SGMT more profitable?

Do analysts prefer KURA or SGMT?

Summary

How does Sagimet Biosciences compare to Esperion Therapeutics?

Do insiders & institutionals have more ownership in ESPR or SGMT?

Do analysts recommend ESPR or SGMT?

Which has more risk and volatility, ESPR or SGMT?

Is ESPR or SGMT more profitable?

Does the media prefer ESPR or SGMT?

Which has stronger valuation & earnings, ESPR or SGMT?

Summary

How does Sagimet Biosciences compare to LB Pharmaceuticals?

Does the media refer more to LBRX or SGMT?

Which has preferable valuation and earnings, LBRX or SGMT?

Do analysts rate LBRX or SGMT?

Do insiders and institutionals believe in LBRX or SGMT?

Is LBRX or SGMT more profitable?

Summary

How does Sagimet Biosciences compare to Sana Biotechnology?

Do institutionals and insiders hold more shares of SGMT or SANA?

Which has more risk & volatility, SGMT or SANA?

Is SGMT or SANA more profitable?

Does the media refer more to SGMT or SANA?

Do analysts rate SGMT or SANA?

Which has better valuation and earnings, SGMT or SANA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SGMT vs. The Competition

Sagimet Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools